Keros Therapeutics (KROS) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to -$0.18.
- Keros Therapeutics' EPS (Weighted Average and Diluted) rose 8723.4% to -$0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.56, marking a year-over-year increase of 12994.24%. This contributed to the annual value of -$5.0 for FY2024, which is 376.15% up from last year.
- Keros Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.18 in Q3 2025, which was up 8723.4% from -$0.76 recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $3.62 in Q1 2025 and a low of -$1.41 during Q3 2024
- In the last 5 years, Keros Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$1.1 in 2022 and averaged -$0.75.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 26984.59% in 2022, then soared by 39917.36% in 2025.
- Over the past 5 years, Keros Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.3 in 2021, then plummeted by 269.85% to -$1.1 in 2022, then decreased by 21.82% to -$1.34 in 2023, then grew by 8.25% to -$1.23 in 2024, then soared by 85.36% to -$0.18 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.18 in Q3 2025, compared to -$0.76 in Q2 2025 and $3.62 in Q1 2025.